| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chloro- manufacturers
|
| | Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chloro- Basic information |
| | Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chloro- Chemical Properties |
| Boiling point | 431.5±30.0 °C(Predicted) | | density | 1.27±0.1 g/cm3(Predicted) | | solubility | DMF: 10 mg/ml; DMSO: 30 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 5 mg/ml | | form | A crystalline solid | | pka | 13.86±0.20(Predicted) |
| | Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chloro- Usage And Synthesis |
| Uses | PNU-282987 is a highly selective α7 nicotinic acetylcholine receptor agonist (1,2). PNU-282,987 has been utilized to generate retinal neurons in the absence of retinal injury or exogenous growth factors in rat (1). PNU-282,987 has the potential to reverse vision loss due to neurodegenerative disease or aging. | | Definition | ChEBI: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide is a carbonyl compound and an organohalogen compound. | | in vivo | PNU-282987 (free base) (Compound C7) (i.v.; 1, 3 mg/kg) leads to a reversal of the gating deficit[1].
PNU-282987 (30 μM) evokes currents in rat hippocampal neurons in a concentration-dependent and MLA blockable manner[1]. | Animal Model: | Rats[1] | | Dosage: | 1, 3 mg/kg | | Administration: | i.v. | | Result: | Significantly reversed amphetamine-induced gating deficit. |
| | IC 50 | 5-HT3 Receptor | | storage | Store at RT |
| | Benzamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chloro- Preparation Products And Raw materials |
|